Working… Menu

Triptorelin for Ovary Protection in Childhood Onset Lupus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00124514
Recruitment Status : Completed
First Posted : July 28, 2005
Last Update Posted : July 28, 2014
Watson Pharmaceuticals
Information provided by (Responsible Party):
Dr. Hermine Brunner, Children's Hospital Medical Center, Cincinnati

Brief Summary:

The purpose of this study is to test the safety of triptorelin when used for the protection of the ovaries (pair of female reproductive organs) during cyclophosphamide therapy for systemic lupus erythematosus (SLE; lupus) and to see what effects (good or bad) it has on patients. The study will be done with female patients who have been diagnosed with systemic lupus erythematosus, are younger than 21 years of age, and require intravenous cyclophosphamide to control the disease. Each patient will be in the study for approximately 23 months, until 4 months after the intravenous cyclophosphamide treatment has been completed.

This study is currently being conducted at 3 sites across the United States and Brazil (Los Angeles, Cincinnati and San Paulo Brazil). A total of 50 patients will participate in this study.

Each patient will be randomized (assigned) to one of 5 groups. Randomization means that patients are put into a group completely by chance. It is like flipping a coin. Neither the patient nor the study staff knows what group the patient is in. The patient has a 20% chance of being placed in any group.

Funding Source: FDA OOPD and Watson Pharmaceuticals

Condition or disease Intervention/treatment Phase
Systemic Lupus Erythematosus Drug: Triptorelin pamoate Phase 2

Detailed Description:

Lupus is an autoimmune disease that may harm all organs in the body and especially affects the kidney, brain, skin and lungs. Cyclophosphamide is a very effective medication to treat lupus, but it can damage the ovaries (pair of reproductive organs).

Only female lupus patients may participate in this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Diagnostic
Study Start Date : June 2003
Actual Primary Completion Date : March 2014
Actual Study Completion Date : March 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Triptorelin Vs Placebo (Normal Saline)
Placebo (Normal Saline) vs triptorelin Pamoate
Drug: Triptorelin pamoate
IM injection given monthly
Other Name: Trelstar Depot

Primary Outcome Measures :
  1. To determine the dose of triptorelin that will maintain complete ovarian suppression between monthly injections [ Time Frame: Patients receive injections every 23-29 days ]
    Patients will receive monthly injections. Exact date and time is recorded. Information will be analyzed to determine length of suppression between injections

Secondary Outcome Measures :
  1. To optimize the time interval at triptorelin injection and infusion of cyclophosphamide [ Time Frame: Monthly ]
    Data will be analyzed to determine best time to give triptorelin injection during cytoxan therapy.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   9 Years to 21 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Females under the age of 21 and non-pregnant
  • Tanner stage of 2 or above as determined by physical examination of breast stage
  • Diagnosis with SLE using the updated American College of Rheumatology (ACR) Classification Criteria for SLE 1
  • Severe SLE requiring cyclophosphamide therapy
  • Bone mineral density z-score > - 2.0
  • Must be using a medically acceptable form of birth control during the study and must not be pregnant at the screening visit
  • No clinically significant abnormal findings other than those consistent with the diagnosis of childhood-onset SLE (cSLE) on the physical examination, medical history or clinical laboratory results during screening
  • Currently on any combination of medication but must not have been treated with more than one dose of cyclophosphamide or other gonadotoxic medications in the past
  • Voluntary consent or, if under the age of consent, assent to participate in this study with permission by a legal guardian

Exclusion Criteria:

  • Male patients of any age
  • Female patients with a Tanner stage of 1
  • Positive blood pregnancy test at screening or taking oral or injectable birth-control medications
  • Prior exposure to more than one dose of gonadotoxic medications including cyclophosphamide
  • History of allergic or adverse response to triptorelin
  • Diagnosed with hypogonadism prior to cyclophosphamide exposure
  • Acutely life-threatening disease activity that prohibits inclusion in a clinical trial
  • History of clinically significant gastrointestinal tract, renal, hepatic, endocrine, oncologic, pulmonary (asthma accepted), or cardiovascular disease; or a history of tuberculosis, epilepsy, diabetes, depression, psychosis, or any other non-cSLE condition, which in the opinion of the physician, would jeopardize the safety of the subject or impact the validity of the study results
  • Patient age 18 years of younger with severe depression as defined by a CDI (Children's Depression Inventory) score of > 23 or a patient age 19 to 21 years with severe depression as defined by a BDI (Beck's Depression Inventory) score > 29
  • Patient admits to suicidal thoughts at screening visit
  • Bone mineral density lower than z = -2.0.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00124514

Layout table for location information
United States, California
Children's Hospital of Los Angeles
Los Angeles, California, United States, 90027
United States, Illinois
Children's Memorial Hospital
Chicago, Illinois, United States, 60614
United States, New Jersey
Hackensack University Medical Center
Hackensack, New Jersey, United States, 07601
United States, New York
Morgan Stanley Children's Hospital of New York
New York, New York, United States, 10032
United States, Ohio
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229
Columbus Children's Hospital
Columbus, Ohio, United States, 43205
United States, Oklahoma
Children's Hospital of Oklahoma
Oklahoma City, Oklahoma, United States, 73104
United States, Washington
Seattle Children's Hospital
Seattle, Washington, United States, 98105
United States, Wisconsin
Children's Hospital of Wisconsin
Milwaukee, Wisconsin, United States, 53226
University of San Paulo
San Paulo, Brazil
Sponsors and Collaborators
Children's Hospital Medical Center, Cincinnati
Watson Pharmaceuticals
Layout table for investigator information
Principal Investigator: Hermine I Brunner, M.D. M.Sc. Children's Hospital Medical Center, Cincinnati

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Dr. Hermine Brunner, Principal Investigator, Children's Hospital Medical Center, Cincinnati Identifier: NCT00124514     History of Changes
Obsolete Identifiers: NCT00088244
Other Study ID Numbers: 2008-1045
FD-R-00239 ( Other Grant/Funding Number: FDA OOPD )
First Posted: July 28, 2005    Key Record Dates
Last Update Posted: July 28, 2014
Last Verified: July 2014
Keywords provided by Dr. Hermine Brunner, Children's Hospital Medical Center, Cincinnati:
Ovarian damage
Additional relevant MeSH terms:
Layout table for MeSH terms
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Triptorelin Pamoate
Luteolytic Agents
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents